News Releases

Friday, October 27, 2017

Top Medicare/Medicaid administrator Seema Verma meets CEO and other UH leaders

CLEVELAND – Administrator of the Centers for Medicare and Medicaid Services
(CMS) Seema Verma met Oct. 23 with University Hospitals CEO Thomas F. Zenty III and other UH leaders to learn more about regulatory burdens placed on hospitals.
 
Her visit was part of a national listening tour on which she has embarked to hear from doctors and providers about how to reduce burdensome regulations so they can focus on providing high quality healthcare to patients. CMS is the U.S. Health Department agency that oversees Medicare and Medicaid.
 

 


Tuesday, October 17, 2017

Nicole Maronian, MD, chosen as new director to lead University Hospitals Ear, Nose & Throat Institute

CLEVELAND – University Hospitals recently announced that accomplished surgeon Nicole Maronian, MD, has been promoted to lead University Hospitals Ear, Nose & Throat (ENT) Institute, effective immediately.
 
As Director of the institute, Dr. Maronian will continue to advance the strategic alignment of ENT across the UH system to ensure consistent excellence in patient care, continued institute growth, ease of patient access and alignment of quality care pathways.

Dr. Maronian is the first female clinical institute leader for University Hospitals. 
 


Tuesday, October 10, 2017

Nature Medicine study: Areas of glioblastoma tumors correlate with separate subtypes of glioma stem cells, respond better to combination treatment

CLEVELAND – A new study published in the Oct. 9 issue of the journal Nature Medicine demonstrates, for the first time, that glioblastoma (GBM), the most common and most lethal brain tumor, is driven by two distinct subsets of cancer stem cells.  Moreover, each subtype of glioma stem cells is driven by distinct transcriptional programs for growth and treatment resistance, and these different cell populations correspond to well-known morphological differences within the GBM itself. 
 
More importantly, the researchers found that while chemotherapeutic agents targeting each subtype achieve modest efficacy alone, they are synergistic when combined as demonstrated in a mouse model.
 
Senior co-author of the study, Andrew Sloan, MD, Medical Director, Brain Tumor and Neuro-Oncology Center at University Hospitals Cleveland Medical Center observed that GBMs typically have two radiologically distinct regions on MRI:  The enhancing mass and the necrotic core.  


Friday, October 06, 2017

UH researcher finds antifungals and probiotics may play key role in development of treatment for Crohn’s disease

CLEVELAND – Scientists have determined that fungus may play a key role in chronic intestinal inflammation disorders. They found that patients with Crohn’s disease tend to have much higher levels of the fungus Candida tropicalis compared to their healthy family members. A new review published in Digestive and Liver Disease looks at these findings and provides insights into potential new therapeutic approaches using antifungals and probiotics in the treatment of inflammatory bowel diseases (IBD) such as Crohn’s disease (CD).
 
“The human gastrointestinal (GI) tract is home to trillions of microorganisms, some beneficial and others potentially harmful. Recent advances in science have allowed us to identify the multitude of organisms inhabiting the GI tract and parse out those that play a role in IBD,” explained lead author Mahmoud A. Ghannoum, PhD, of the Center for Medical Mycology, Department of Dermatology, Case Western Reserve University and, University Hospitals Cleveland Medical Center. “Unfortunately, most research has focused on studying only the bacteria while overlooking a key player, fungus. In order to address this issue, we have focused our efforts on studying the fungal community in the GI tract known as the mycobiome.”


Tuesday, September 12, 2017

SummaCare, University Hospitals forge Medicare collaboration

AKRON – Building on a relationship that has been in place since 2007, SummaCare and University Hospitals (UH) today announced a new collaborative agreement to co-brand existing SummaCare Medicare products in markets where UH facilities are located. Known as University Hospitals Medicare Advantage from SummaCare, the collaborative agreement highlights the trusted reputations of SummaCare’s 22-year-old Medicare Advantage plans and UH’s comprehensive network of high-quality providers.
 
The collaborative agreement was designed to encourage the health plan, hospitals and doctors to provide coordinated, holistic care, rather than traditional, fee-for-service health care. This approach leads to improved health outcomes for patients and members. As part of the agreement, UH will provide dedicated care managers and coordination services, in collaboration with SummaCare, to assist members with utilizing benefits and taking advantage of opportunities to lead healthier lives.
 
“This is a vital collaboration that will prove beneficial to both organizations, and most importantly, to our Medicare Advantage members,” said Anne Armao, SummaCare vice president, Marketing and Consumer Engagement. “We expect our members to achieve improved quality of care, better health outcomes and an overall outstanding patient experience.”



You must be logged in to view this item.



Login

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.